Reaction
Application Site Dermatitis reporting signals
As of the last recalculation, Application Site Dermatitis appears in 928 FAERS reports alongside 12 co-occurring drug terms. The strongest observed disproportionality signal is NICOTINE (PRR 187.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Nicotine | 248 | 187.3 | 188.5 |
| Rotigotine | 19 | 30.1 | 30.1 |
| Buprenorphine | 70 | 18.3 | 18.3 |
| Nicotine Polacrilex Mini | 10 | 15.1 | 15.1 |
| Nicotine Polarilex | 10 | 15.1 | 15.1 |
| Rivastigmine | 12 | 14.5 | 14.5 |
| Methylphenidate | 13 | 10.2 | 10.2 |
| Nicotine Polacrilex | 17 | 10.1 | 10.1 |
| Minoxidil Foam 5% (Womens) | 12 | 8.3 | 8.3 |
| Minoxidil | 15 | 7.6 | 7.6 |
| Glycerin, Lidocaine | 3 | 4.8 | 4.8 |
| Docosanol | 3 | 4.6 | 4.6 |